Dr Bose on the Use of Zilurgisertib With/Without Ruxolitinib

Prithviraj Bose, MD, discusses key data on the use of zilurgisertib alone or in combination with ruxolitinib to reduce disease-related anemia in patients with primary or secondary myelofibrosis.

Related Keywords

Texas , United States , Prithviraj Bose , University Of Texas Md Anderson Cancer Center , Division Of Cancer Medicine , Department Of Leukemia , Cancer Medicine , Cancer Center , Myeloproliferative Neoplasms , Myelofibrosis , Mdanderson , Spleen Volume , Asco 2023 , Zilurgisertib , Ruxolitinib , Anemia ,